An emerging role for the anti-inflammatory cytokine interleukin-10 in dengue virus infection

Journal of Biomedical Science

Volumn 20, Issue 1, 2013, Pages

  Tsai, Tsung Ting ^a   Chuang, Yi Jui ^a   Lin, Yee Shin ^a,b   Wan, Shu Wen ^a,b   Chen, Chia Ling ^a,b   Lin, Chiou Feng ^a,b  

^a NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

^b NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

Author keywords

Antibody dependent enhancement; DENV; IL 10; Immunopathogenesis; Infection

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 19; INTERLEUKIN 20; INTERLEUKIN 22; INTERLEUKIN 24; SUPPRESSOR OF CYTOKINE SIGNALING; TOLL LIKE RECEPTOR; VIRUS RNA; ANTIINFLAMMATORY AGENT;

ANTIBODY DEPENDENT ENHANCEMENT; AUTOIMMUNITY; CELL ACTIVATION; CLINICAL FEATURE; DENGUE; DENGUE VIRUS; DISEASE SEVERITY; HELPER CELL; HUMAN; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNOPATHOGENESIS; IMMUNOREGULATION; NATURAL KILLER CELL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; REVIEW; VIRUS LOAD; IMMUNOLOGY; METABOLISM; PATHOLOGY; PHYSIOLOGY;

DENGUE VIRUS;

ANTI-INFLAMMATORY AGENTS; DENGUE; DENGUE VIRUS; HUMANS; INTERLEUKIN-10;

EID: 84879209749     PISSN: 10217770     EISSN: 14230127     Source Type: Journal    
DOI: 10.1186/1423-0127-20-40     Document Type: Review

References (130)

1. Dengue. Diaz-Quijano FA, N Engl J Med 2012 367 180 author reply 181 22784126
2. Multicentre prospective study on dengue classification in four South-east Asian and three Latin American countries. Alexander N, Balmaseda A, Coelho IC, Dimaano E, Hien TT, Hung NT, Janisch T, Kroeger A, Lum LC, Martinez E, et al. Trop med int health TM IH 2011 16 936 948 10.1111/j.1365-3156.2011.02793.x
3. Dengue: a continuing global threat. Guzman MG, Halstead SB, Artsob H, Buchy P, Farrar J, Gubler DJ, Hunsperger E, Kroeger A, Margolis HS, Martinez E, et al. Nat Rev Microbiol 2010 8 7 S16 10.1038/nrmicro2460 21079655
4. Innate immunity evasion by Dengue virus. Morrison J, Aguirre S, Fernandez-Sesma A, Viruses 2012 4 397 413 10.3390/v4030397 22590678
5. Structural proteomics of dengue virus. Perera R, Kuhn RJ, Curr Opin Microbiol 2008 11 369 377 10.1016/j.mib.2008.06.004 18644250
6. Recent advances in deciphering viral and host determinants of dengue virus replication and pathogenesis. Clyde K, Kyle JL, Harris E, J Virol 2006 80 11418 11431 10.1128/JVI.01257-06 16928749 (Pubitemid 44788858)
7. Dengue virus life cycle: viral and host factors modulating infectivity. Rodenhuis-Zybert IA, Wilschut J, Smit JM, Cell mol life sci CMLS 2010 67 2773 2786 10.1007/s00018-010-0357-z
8. Dengue virus infectivity depends on envelope protein binding to target cell heparan sulfate. Chen Y, Maguire T, Hileman RE, Fromm JR, Esko JD, Linhardt RJ, Marks RM, Nature med 1997 3 866 871 10.1038/nm0897-866 9256277 (Pubitemid 27353446)
9. Bacterial lipopolysaccharide inhibits dengue virus infection of primary human monocytes/macrophages by blockade of virus entry via a CD14-dependent mechanism. Chen YC, Wang SY, King CC, J Virol 1999 73 2650 2657 10074110
10. DC-SIGN (CD209) mediates dengue virus infection of human dendritic cells. Tassaneetrithep B, Burgess TH, Granelli-Piperno A, Trumpfheller C, Finke J, Sun W, Eller MA, Pattanapanyasat K, Sarasombath S, Birx DL, et al. J exper med 2003 197 823 829 10.1084/jem.20021840 (Pubitemid 36437860)
11. Identification of GRP 78 (BiP) as a liver cell expressed receptor element for dengue virus serotype 2. Jindadamrongwech S, Thepparit C, Smith DR, Arch Virol 2004 149 915 927 10.1007/s00705-003-0263-x 15098107 (Pubitemid 38641472)
12. Serotype-specific entry of dengue virus into liver cells: identification of the 37-kilodalton/67-kilodalton high-affinity laminin receptor as a dengue virus serotype 1 receptor. Thepparit C, Smith DR, J Virol 2004 78 12647 12656 10.1128/JVI.78.22.12647-12656.2004 15507651 (Pubitemid 39458782)
13. Heat shock protein 90 and heat shock protein 70 are components of dengue virus receptor complex in human cells. Reyes-Del Valle J, Chavez-Salinas S, Medina F, Del Angel RM, J Virol 2005 79 4557 4567 10.1128/JVI.79.8.4557-4567. 2005 15795242 (Pubitemid 40464207)
14. The mannose receptor mediates dengue virus infection of macrophages. Miller JL, de Wet BJ, Martinez-Pomares L, Radcliffe CM, Dwek RA, Rudd PM, Gordon S, PLoS pathogens 2008 4 17 10.1371/journal.ppat.0040017 18266465 (Pubitemid 351340711)
15. CLEC5A is critical for dengue-virus-induced lethal disease. Chen ST, Lin YL, Huang MT, Wu MF, Cheng SC, Lei HY, Lee CK, Chiou TW, Wong CH, Hsieh SL, Nature 2008 453 672 676 10.1038/nature07013 18496526 (Pubitemid 351769308)
16. Endothelial cell surface expression of protein disulfide isomerase activates beta1 and beta3 integrins and facilitates dengue virus infection. Wan SW, Lin CF, Lu YT, Lei HY, Anderson R, Lin YS, J Cell Biochem 2012 113 1681 1691 22422622
17. Proper processing of dengue virus nonstructural glycoprotein NS1 requires the N-terminal hydrophobic signal sequence and the downstream nonstructural protein NS2a. Falgout B, Chanock R, Lai CJ, J Virol 1989 63 1852 1860 2522997 (Pubitemid 19107777)
18. Vimentin interacts with heterogeneous nuclear ribonucleoproteins and dengue nonstructural protein 1 and is important for viral replication and release. Kanlaya R, Pattanakitsakul SN, Sinchaikul S, Chen ST, Thongboonkerd V, Mol Biosyst 2010 6 795 806 10.1039/b923864f 20567765
19. Genetic interaction of flavivirus nonstructural proteins NS1 and NS4A as a determinant of replicase function. Lindenbach BD, Rice CM, J Virol 1999 73 4611 4621 10233920 (Pubitemid 29246719)
20. Dengue virus NS4B interacts with NS3 and dissociates it from single-stranded RNA. Umareddy I, Chao A, Sampath A, Gu F, Vasudevan SG, J Gen Virol 2006 87 2605 2614 10.1099/vir.0.81844-0 16894199
21. Human antibody to dengue soluble complement-fixing (SCF) antigens. Falkler WA Jr, Diwan AR, Halstead SB, J Immunol 1973 111 1804 1809 4201557
22. Vascular leakage in severe dengue virus infections: a potential role for the nonstructural viral protein NS1 and complement. Avirutnan P, Punyadee N, Noisakran S, Komoltri C, Thiemmeca S, Auethavornanan K, Jairungsri A, Kanlaya R, Tangthawornchaikul N, Puttikhunt C, et al. J Infect Dis 2006 193 1078 1088 10.1086/500949 16544248
23. Binding of flavivirus nonstructural protein NS1 to C4b binding protein modulates complement activation. Avirutnan P, Hauhart RE, Somnuke P, Blom AM, Diamond MS, Atkinson JP, J Immunol 2011 187 424 433 10.4049/jimmunol.1100750 21642539
24. Dengue virus infection: predictors for severe dengue. Pawitan JA, Acta medica Indonesiana 2011 43 129 135 21785176
25. A structural basis for the inhibition of the NS5 dengue virus mRNA 2′-O-methyltransferase domain by ribavirin 5′-triphosphate. Benarroch D, Egloff MP, Mulard L, Guerreiro C, Romette JL, Canard B, J Biol Chem 2004 279 35638 35643 10.1074/jbc.M400460200 15152003 (Pubitemid 39100566)
26. Recombinant dengue type 1 virus NS5 protein expressed in Escherichia coli exhibits RNA-dependent RNA polymerase activity. Tan BH, Fu J, Sugrue RJ, Yap EH, Chan YC, Tan YH, Virology 1996 216 317 325 10.1006/viro.1996.0067 8607261 (Pubitemid 26083377)
27. Association between NS3 and NS5 proteins of dengue virus type 2 in the putative RNA replicase is linked to differential phosphorylation of NS5. Kapoor M, Zhang L, Ramachandra M, Kusukawa J, Ebner KE, Padmanabhan R, J Biol Chem 1995 270 19100 19106 10.1074/jbc.270.32.19100 7642575
28. Nuclear localization of dengue virus nonstructural protein 5 through its importin alpha/beta-recognized nuclear localization sequences is integral to viral infection. Pryor MJ, Rawlinson SM, Butcher RE, Barton CL, Waterhouse TA, Vasudevan SG, Bardin PG, Wright PJ, Jans DA, Davidson AD, Traffic 2007 8 795 807 10.1111/j.1600-0854.2007.00579.x 17537211 (Pubitemid 46971628)
29. Immune response to dengue virus and prospects for a vaccine. Murphy BR, Whitehead SS, Annu Rev Immunol 2011 29 587 619 10.1146/annurev-immunol-031210- 101315 21219187
30. Dengue. Simmons CP, Farrar JJ, Nguyen V, Wills B, N Engl J Med 2012 366 1423 1432 10.1056/NEJMra1110265 22494122
31. Critical issues in dengue vaccine development. Thomas SJ, Endy TP, Curr Opin Infect Dis 2011 24 442 450 10.1097/QCO.0b013e32834a1b0b 21799408
32. Controversies in dengue pathogenesis. Halstead SB, Paediatrics inter child health 2012 32 Suppl 1 5 9
33. Autoimmunity in dengue pathogenesis. Wan SW, Lin CF, Yeh TM, Liu CC, Liu HS, Wang S, Ling P, Anderson R, Lei HY, Lin YS, J Formosan Med Assoc = Taiwan yi zhi 2013 112 3 11 10.1016/j.jfma.2012.11.006
34. Allergies and diabetes as risk factors for dengue hemorrhagic fever: results of a case control study. Figueiredo MA, Rodrigues LC, Barreto ML, Lima JW, Costa MC, Morato V, Blanton R, Vasconcelos PF, Nunes MR, Teixeira MG, PLoS Negl Trop Dis 2010 4 699 10.1371/journal.pntd.0000699 20532230
35. Diabetes with hypertension as risk factors for adult dengue hemorrhagic fever in a predominantly dengue serotype 2 epidemic: a case control study. Pang J, Salim A, Lee VJ, Hibberd ML, Chia KS, Leo YS, Lye DC, PLoS Negl Trop Dis 2012 6 1641 10.1371/journal.pntd.0001641 22563519
36. Dengue and dengue hemorrhagic fever among adults: clinical outcomes related to viremia, serotypes, and antibody response. Guilarde AO, Turchi MD, Siqueira JB Jr, Feres VC, Rocha B, Levi JE, Souza VA, Boas LS, Pannuti CS, Martelli CM, J Infect Dis 2008 197 817 824 10.1086/528805 18269315 (Pubitemid 351417004)
37. Host genetic susceptibility to severe dengue infection. Lan NT, Hirayama K, Tropical med health 2011 39 73 81 10.2149/tmh.2011-02
38. Immunity to dengue virus: a tale of original antigenic sin and tropical cytokine storms. Rothman AL, Nat Rev Immunol 2011 11 532 543 10.1038/nri3014 21760609
39. Dengue viremia titer, antibody response pattern, and virus serotype correlate with disease severity. Vaughn DW, Green S, Kalayanarooj S, Innis BL, Nimmannitya S, Suntayakorn S, Endy TP, Raengsakulrach B, Rothman AL, Ennis FA, Nisalak A, J Infect Dis 2000 181 2 9 10.1086/315215 10608744 (Pubitemid 30049026)
40. American genotype structures decrease dengue virus output from human monocytes and dendritic cells. Cologna R, Rico-Hesse R, J Virol 2003 77 3929 3938 10.1128/JVI.77.7.3929-3938.2003 12634353 (Pubitemid 36350934)
41. Phenotypic and genotypic characterization of dengue virus isolates differentiates dengue fever and dengue hemorrhagic fever from dengue shock syndrome. Tuiskunen A, Monteil V, Plumet S, Boubis L, Wahlstrom M, Duong V, Buchy P, Lundkvist A, Tolou H, Leparc-Goffart I, Arch Virol 2011 156 2023 2032 10.1007/s00705-011-1100-2 21922323
42. Analysis of plasma viral RNA levels during acute dengue virus infection using quantitative competitor reverse transcription-polymerase chain reaction. Sudiro TM, Zivny J, Ishiko H, Green S, Vaughn DW, Kalayanarooj S, Nisalak A, Norman JE, Ennis FA, Rothman AL, J Med Virol 2001 63 29 34 10.1002/1096- 9071(200101)63:1<29::AID-JMV1004>3.0.CO;2-S 11130884
43. High levels of plasma dengue viral load during defervescence in patients with dengue hemorrhagic fever: implications for pathogenesis. Wang WK, Chao DY, Kao CL, Wu HC, Liu YC, Li CM, Lin SC, Ho ST, Huang JH, King CC, Virology 2003 305 330 338 10.1006/viro.2002.1704 12573578 (Pubitemid 36259667)
44. Dengue virus inhibits alpha interferon signaling by reducing STAT2 expression. Jones M, Davidson A, Hibbert L, Gruenwald P, Schlaak J, Ball S, Foster GR, Jacobs M, J Virol 2005 79 5414 5420 10.1128/JVI.79.9.5414-5420.2005 15827155 (Pubitemid 40548209)
45. Dengue virus NS5 inhibits interferon-alpha signaling by blocking signal transducer and activator of transcription 2 phosphorylation. Mazzon M, Jones M, Davidson A, Chain B, Jacobs M, J Infect Dis 2009 200 1261 1270 10.1086/605847 19754307
46. Inhibition of alpha/beta interferon signaling by the NS4B protein of flaviviruses. Munoz-Jordan JL, Laurent-Rolle M, Ashour J, Martinez-Sobrido L, Ashok M, Lipkin WI, Garcia-Sastre A, J Virol 2005 79 8004 8013 10.1128/JVI.79.13.8004-8013.2005 15956546 (Pubitemid 40853504)
47. Inhibition of interferon signaling by dengue virus. Munoz-Jordan JL, Sanchez-Burgos GG, Laurent-Rolle M, Garcia-Sastre A, Proc Natl Acad Sci USA 2003 100 14333 14338 10.1073/pnas.2335168100 14612562 (Pubitemid 37499237)
48. Evasion of the human innate immune system by dengue virus. Pagni S, Fernandez-Sesma A, Immunol Res 2012 54 1-3 152 159 10.1007/s12026-012-8334-2 22569913
49. Early immune activation in acute dengue illness is related to development of plasma leakage and disease severity. Green S, Vaughn DW, Kalayanarooj S, Nimmannitya S, Suntayakorn S, Nisalak A, Lew R, Innis BL, Kurane I, Rothman AL, Ennis FA, J Infect Dis 1999 179 755 762 10.1086/314680 10068569 (Pubitemid 29159319)
50. Elevated plasma interleukin-10 levels in acute dengue correlate with disease severity. Green S, Vaughn DW, Kalayanarooj S, Nimmannitya S, Suntayakorn S, Nisalak A, Rothman AL, Ennis FA, J Med Virol 1999 59 329 334 10.1002/(SICI)1096-9071(199911)59:3<329::AID-JMV12>3.0.CO;2-G 10502265 (Pubitemid 29468075)
51. Dengue virus infects human endothelial cells and induces IL-6 and IL-8 production. Huang YH, Lei HY, Liu HS, Lin YS, Liu CC, Yeh TM, Am J Trop Med Hyg 2000 63 71 75 11357999
52. High levels of interferon alpha in the sera of children with dengue virus infection. Kurane I, Innis BL, Nimmannitya S, Nisalak A, Meager A, Ennis FA, Am J Trop Med Hyg 1993 48 222 229 8447527 (Pubitemid 23083739)
53. Activation of T lymphocytes in dengue virus infections. High levels of soluble interleukin 2 receptor, soluble CD4, soluble CD8, interleukin 2, and interferon-gamma in sera of children with dengue. Kurane I, Innis BL, Nimmannitya S, Nisalak A, Meager A, Janus J, Ennis FA, J Clin Invest 1991 88 1473 1480 10.1172/JCI115457 1939640
54. Dengue virus infection of human skin fibroblasts in vitro production of IFN-beta, IL-6 and GM-CSF. Kurane I, Janus J, Ennis FA, Arch Virol 1992 124 21 30 10.1007/BF01314622 1571018
55. Intrinsic antibody-dependent enhancement of microbial infection in macrophages: disease regulation by immune complexes. Halstead SB, Mahalingam S, Marovich MA, Ubol S, Mosser DM, Lancet Infect Dis 2010 10 712 722 10.1016/S1473-3099(10)70166-3 20883967
56. Markers of dengue disease severity. Srikiatkhachorn A, Green S, Curr Top Microbiol Immunol 2010 338 67 82 10.1007/978-3-642-02215-9-6 19802579
57. Generation of IgM anti-platelet autoantibody in dengue patients. Lin CF, Lei HY, Liu CC, Liu HS, Yeh TM, Wang ST, Yang TI, Sheu FC, Kuo CF, Lin YS, J Med Virol 2001 63 143 149 10.1002/1096-9071(20000201)63:2<143::AID-JMV1009>3. 0.CO;2-L 11170051
58. Antibodies from dengue patient sera cross-react with endothelial cells and induce damage. Lin CF, Lei HY, Shiau AL, Liu CC, Liu HS, Yeh TM, Chen SH, Lin YS, J Med Virol 2003 69 82 90 10.1002/jmv.10261 12436482 (Pubitemid 35403658)
59. Immunopathological mechanisms in dengue and dengue hemorrhagic fever. Green S, Rothman A, Curr Opin Infect Dis 2006 19 429 436 10.1097/01.qco. 0000244047.31135.fa 16940865 (Pubitemid 44338101)
60. Autoimmune pathogenesis in dengue virus infection. Lin CF, Wan SW, Cheng HJ, Lei HY, Lin YS, Viral immunology 2006 19 127 132 10.1089/vim.2006.19.127 16817755 (Pubitemid 44050311)
61. Molecular mimicry between virus and host and its implications for dengue disease pathogenesis. Lin YS, Yeh TM, Lin CF, Wan SW, Chuang YC, Hsu TK, Liu HS, Liu CC, Anderson R, Lei HY, Exp Biol Med (Maywood) 2011 236 515 523 10.1258/ebm.2011.010339
62. Of cascades and perfect storms: the immunopathogenesis of dengue haemorrhagic fever-dengue shock syndrome (DHF/DSS). Pang T, Cardosa MJ, Guzman MG, Immunol Cell Biol 2007 85 43 45 10.1038/sj.icb.7100008 17130899 (Pubitemid 46067320)
63. Deletion of the C-terminal region of dengue virus nonstructural protein 1 (NS1) abolishes anti-NS1-mediated platelet dysfunction and bleeding tendency. Chen MC, Lin CF, Lei HY, Lin SC, Liu HS, Yeh TM, Anderson R, Lin YS, J Immunol 2009 183 1797 1803 10.4049/jimmunol.0800672 19592650
64. Antibodies against dengue virus E protein peptide bind to human plasminogen and inhibit plasmin activity. Huang YH, Chang BI, Lei HY, Liu HS, Liu CC, Wu HL, Yeh TM, Clin Exp Immunol 1997 110 35 40 10.1111/j.1365-2249.1997. 499-ce1398.x 9353146 (Pubitemid 27428512)
65. The dual-specific binding of dengue virus and target cells for the antibody-dependent enhancement of dengue virus infection. Huang KJ, Yang YC, Lin YS, Huang JH, Liu HS, Yeh TM, Chen SH, Liu CC, Lei HY, J Immunol 2006 176 2825 2832 16493039
66. Role of dendritic cells in antibody-dependent enhancement of dengue virus infection. Boonnak K, Slike BM, Burgess TH, Mason RM, Wu SJ, Sun P, Porter K, Rudiman IF, Yuwono D, Puthavathana P, Marovich MA, J Virol 2008 82 3939 3951 10.1128/JVI.02484-07 18272578 (Pubitemid 351521231)
67. Monoclonal antibody-mediated enhancement of dengue virus infection in vitro and in vivo and strategies for prevention. Goncalvez AP, Engle RE, St Claire M, Purcell RH, Lai CJ, Proc Nat Acad Sci United States Am 2007 104 9422 9427 10.1073/pnas.0703498104 (Pubitemid 47185795)
68. Neutralization and antibody-dependent enhancement of dengue viruses. Halstead SB, Adv virus res 2003 60 421 467 14689700 (Pubitemid 137639381)
69. Mechanisms of immune evasion induced by a complex of dengue virus and preexisting enhancing antibodies. Ubol S, Phuklia W, Kalayanarooj S, Modhiran N, J Infect Dis 2010 201 923 935 10.1086/651018 20158392
70. Dengue virus (DENV) antibody-dependent enhancement of infection upregulates the production of anti-inflammatory cytokines, but suppresses anti-DENV free radical and pro-inflammatory cytokine production, in THP-1 cells. Chareonsirisuthigul T, Kalayanarooj S, Ubol S, J Gen Virol 2007 88 365 375 10.1099/vir.0.82537-0 17251552 (Pubitemid 46210873)
71. IL-10: the master regulator of immunity to infection. Couper KN, Blount DG, Riley EM, J Immunol 2008 180 5771 5777 18424693
72. The role of IL-10 in regulating immunity to persistent viral infections. Wilson EB, Brooks DG, Curr Top Microbiol Immunol 2011 350 39 65 20703965
73. Two types of mouse T helper cell. IV. Th2 clones secrete a factor that inhibits cytokine production by Th1 clones. Fiorentino DF, Bond MW, Mosmann TR, J exper med 1989 170 2081 2095 10.1084/jem.170.6.2081 (Pubitemid 20010086)
74. Expression profiling of IL-10-regulated genes in human monocytes and peripheral blood mononuclear cells from psoriatic patients during IL-10 therapy. Jung M, Sabat R, Kratzschmar J, Seidel H, Wolk K, Schonbein C, Schutt S, Friedrich M, Docke WD, Asadullah K, et al. Eur J Immunol 2004 34 481 493 10.1002/eji.200324323 14768053 (Pubitemid 39255958)
75. The interleukin-10 family of cytokines. Fickenscher H, Hor S, Kupers H, Knappe A, Wittmann S, Sticht H, Trends in immunology 2002 23 89 96 10.1016/S1471-4906(01)02149-4 11929132 (Pubitemid 34310150)
76. The family of IL-10-related cytokines and their receptors: related, but to what extent? Kotenko SV, Cytokine growth factor rev 2002 13 223 240 10.1016/S1359-6101(02)00012-6 12486876 (Pubitemid 34693176)
77. Conformational changes mediate interleukin-10 receptor 2 (IL-10R2) binding to IL-10 and assembly of the signaling complex. Yoon SI, Logsdon NJ, Sheikh F, Donnelly RP, Walter MR, J Biol Chem 2006 281 35088 35096 10.1074/jbc.M606791200 16982608 (Pubitemid 46036548)
78. IL-10 induces the tyrosine phosphorylation of tyk2 and Jak1 and the differential assembly of STAT1 alpha and STAT3 complexes in human T cells and monocytes. Finbloom DS, Winestock KD, J Immunol 1995 155 1079 1090 7543512
79. Stat3 recruitment by two distinct ligand-induced, tyrosine-phosphorylated docking sites in the interleukin-10 receptor intracellular domain. Weber-Nordt RM, Riley JK, Greenlund AC, Moore KW, Darnell JE, Schreiber RD, J Biol Chem 1996 271 27954 27961 10.1074/jbc.271.44.27954 8910398 (Pubitemid 26367376)
80. Biology of interleukin-10. Sabat R, Grutz G, Warszawska K, Kirsch S, Witte E, Wolk K, Geginat J, Cytokine growth factor rev 2010 21 331 344 10.1016/j.cytogfr.2010.09.002 21115385
81. Recent insights into microbial triggers of interleukin-10 production in the host and the impact on infectious disease pathogenesis. Duell BL, Tan CK, Carey AJ, Wu F, Cripps AW, Ulett GC, FEMS Immunol Med Microbiol 2012 64 295 313 10.1111/j.1574-695X.2012.00931.x 22268692
82. Staphylococcus aureus induces microglial inflammation via a glycogen synthase kinase 3beta-regulated pathway. Cheng YL, Wang CY, Huang WC, Tsai CC, Chen CL, Shen CF, Chi CY, Lin CF, Infect Immun 2009 77 4002 4008 10.1128/IAI.00176-09 19596777
83. IL-10 regulation by HIV-Tat in primary human monocytic cells: involvement of calmodulin/calmodulin-dependent protein kinase-activated p38 MAPK and Sp-1 and CREB-1 transcription factors. Gee K, Angel JB, Mishra S, Blahoianu MA, Kumar A, J Immunol 2007 178 798 807 17202341 (Pubitemid 46095152)
84. Protein kinase C delta (PKCdelta)-extracellular signal-regulated kinase 1/2 (ERK1/2) signaling cascade regulates glycogen synthase kinase-3 (GSK-3) inhibition-mediated interleukin-10 (IL-10) expression in lipopolysaccharide (LPS)-induced endotoxemia. Noh KT, Son KH, Jung ID, Kang HK, Hwang SA, Lee WS, You JC, Park YM, J Biol Chem 2012 287 14226 14233 10.1074/jbc.M111.308841 22393041
85. Characterisation of lymphocyte response and cytokine patterns in patients with dengue fever. Azeredo EL, Zagne SM, Santiago MA, Gouvea AS, Santana AA, Neves-Souza PC, Nogueira RM, Miagostovich MP, Kubelka CF, Immunobiology 2001 204 494 507 10.1078/0171-2985-00058 11776403 (Pubitemid 33138110)
86. Correlation of serum levels of macrophage migration inhibitory factor with disease severity and clinical outcome in dengue patients. Chen LC, Lei HY, Liu CC, Shiesh SC, Chen SH, Liu HS, Lin YS, Wang ST, Shyu HW, Yeh TM, Am J Trop Med Hyg 2006 74 142 147 16407359
87. Altered T helper 1 reaction but not increase of virus load in patients with dengue hemorrhagic fever. Chen RF, Liu JW, Yeh WT, Wang L, Chang JC, Yu HR, Cheng JT, Yang KD, FEMS Immunol Med Microbiol 2005 44 43 50 10.1016/j.femsim.2004.11.012 15780577 (Pubitemid 40380900)
88. High plasma levels of soluble ST2 but not its ligand IL-33 is associated with severe forms of pediatric dengue. Guerrero CD, Arrieta AF, Ramirez ND, Rodriguez LS, Vega R, Bosch I, Rodriguez JA, Narvaez CF, Salgado DM, Cytokine 2013 61 766 771 10.1016/j.cyto.2012.12.024 23357301
89. Levels of soluble ST2 in serum associated with severity of dengue due to tumour necrosis factor alpha stimulation. Houghton-Trivino N, Salgado DM, Rodriguez JA, Bosch I, Castellanos JE, J Gen Virol 2010 91 697 706 10.1099/vir.0.012971-0 19889931
90. Differing influences of virus burden and immune activation on disease severity in secondary dengue-3 virus infections. Libraty DH, Endy TP, Houng HS, Green S, Kalayanarooj S, Suntayakorn S, Chansiriwongs W, Vaughn DW, Nisalak A, Ennis FA, Rothman AL, J Infect Dis 2002 185 1213 1221 10.1086/340365 12001037 (Pubitemid 34439127)
91. Dengue hemorrhagic fever in infants: a study of clinical and cytokine profiles. Nguyen TH, Lei HY, Nguyen TL, Lin YS, Huang KJ, Le BL, Lin CF, Yeh TM, Do QH, Vu TQ, et al. J Infect Dis 2004 189 221 232 10.1086/380762 14722886 (Pubitemid 38147245)
92. IL-10 levels in Dengue patients: some findings from the exceptional epidemiological conditions in Cuba. Perez AB, Garcia G, Sierra B, Alvarez M, Vazquez S, Cabrera MV, Rodriguez R, Rosario D, Martinez E, Denny T, Guzman MG, J Med Virol 2004 73 230 234 10.1002/jmv.20080 15122797 (Pubitemid 38542677)
93. Alteration of cytokines and chemokines during febrile episodes associated with endothelial cell damage and plasma leakage in dengue hemorrhagic fever. Butthep P, Chunhakan S, Yoksan S, Tangnararatchakit K, Chuansumrit A, Pediatr Infect Dis J 2012 31 12 232 e238 10.1097/INF.0b013e31826fd456 22926216
94. A three-component biomarker panel for prediction of dengue hemorrhagic fever. Brasier AR, Ju H, Garcia J, Spratt HM, Victor SS, Forshey BM, Halsey ES, Comach G, Sierra G, Blair PJ, et al. Am J Trop Med Hyg 2012 86 341 348 10.4269/ajtmh.2012.11-0469 22302872
95. Both viremia and cytokine levels associate with the lack of severe disease in secondary dengue 1 infection among adult Chinese patients. Tang Y, Kou Z, Zhang F, Yao X, Liu S, Ma J, Zhou Y, Zhao W, Tang X, Jin X, PLoS One 2010 5 15631 10.1371/journal.pone.0015631 21206915
96. Implications of previous subclinical dengue infection but not virus load in dengue hemorrhagic fever. Yeh WT, Chen RF, Wang L, Liu JW, Shaio MF, Yang KD, FEMS Immunol Med Microbiol 2006 48 84 90 10.1111/j.1574-695X.2006.00127.x 16965355 (Pubitemid 44379223)
97. Increased frequencies of CD4+ CD25(high) regulatory T cells in acute dengue infection. Luhn K, Simmons CP, Moran E, Dung NT, Chau TN, Quyen NT, le Thao TT, Van Ngoc T, Dung NM, Wills B, et al. J exper med 2007 204 979 985 10.1084/jem.20061381 (Pubitemid 46798142)
98. Cell type specificity and host genetic polymorphisms influence antibody-dependent enhancement of dengue virus infection. Boonnak K, Dambach KM, Donofrio GC, Tassaneetrithep B, Marovich MA, J Virol 2011 85 1671 1683 10.1128/JVI.00220-10 21123382
99. Interleukin-10: new perspectives on an old cytokine. Mosser DM, Zhang X, Immunol Rev 2008 226 205 218 10.1111/j.1600-065X.2008.00706.x 19161426
100. The regulation of IL-10 production by immune cells. Saraiva M, O'Garra A, Nat Rev Immunol 2010 10 170 181 10.1038/nri2711 20154735
101. Toll-like receptor-mediated cytokine production is differentially regulated by glycogen synthase kinase 3. Martin M, Rehani K, Jope RS, Michalek SM, Nat Immunol 2005 6 777 784 16007092 (Pubitemid 43090463)
102. GSK3: an in-Toll-erant protein kinase? Woodgett JR, Ohashi PS, Nat Immunol 2005 6 751 752 16034428 (Pubitemid 43090457)
103. Glycogen synthase kinase-3beta mediates endoplasmic reticulum stress-induced lysosomal apoptosis in leukemia. Huang WC, Lin YS, Chen CL, Wang CY, Chiu WH, Lin CF, J Pharmacol Exp Ther 2009 329 524 531 10.1124/jpet.108. 148122 19188482
104. IFN-gamma suppresses IL-10 production and synergizes with TLR2 by regulating GSK3 and CREB/AP-1 proteins. Hu X, Paik PK, Chen J, Yarilina A, Kockeritz L, Lu TT, Woodgett JR, Ivashkiv LB, Immunity 2006 24 563 574 10.1016/j.immuni.2006.02.014 16713974 (Pubitemid 43728157)
105. IFN-gamma synergizes with LPS to induce nitric oxide biosynthesis through glycogen synthase kinase-3-inhibited IL-10. Lin CF, Tsai CC, Huang WC, Wang CY, Tseng HC, Wang Y, Kai JI, Wang SW, Cheng YL, J Cell Biochem 2008 105 746 755 10.1002/jcb.21868 18655171
106. Transcriptional regulation by the phosphorylation-dependent factor CREB. Mayr B, Montminy M, Nat Rev Mol Cell Biol 2001 2 599 609 10.1038/35085068 11483993 (Pubitemid 33674011)
107. Molecular actions and therapeutic potential of lithium in preclinical and clinical studies of CNS disorders. Chiu CT, Chuang DM, Pharmacol Ther 2010 128 281 304 10.1016/j.pharmthera.2010.07.006 20705090
108. A secondary phosphorylation of CREB341 at Ser129 is required for the cAMP-mediated control of gene expression. A role for glycogen synthase kinase-3 in the control of gene expression. Fiol CJ, Williams JS, Chou CH, Wang QM, Roach PJ, Andrisani OM, J Biol Chem 1994 269 32187 32193 7798217
109. Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. Cross DA, Alessi DR, Cohen P, Andjelkovich M, Hemmings BA, Nature 1995 378 785 789 10.1038/378785a0 8524413 (Pubitemid 26004411)
110. Phosphorylation and inactivation of glycogen synthase kinase 3 by protein kinase A. Fang X, Yu SX, Lu Y, Bast RC Jr, Woodgett JR, Mills GB, Proc Natl Acad Sci U S A 2000 97 11960 11965 10.1073/pnas.220413597 11035810
111. Myeloid cell IL-10 production in response to leishmania involves inactivation of glycogen synthase kinase-3beta downstream of phosphatidylinositol-3 kinase. Nandan D, Camargo De Oliveira C, Moeenrezakhanlou A, Lopez M, Silverman JM, Subek J, Reiner NE, J Immunol 2012 188 367 378 10.4049/jimmunol.1100076 22140263
112. Latent membrane protein 1 of EBV activates phosphatidylinositol 3-kinase to induce production of IL-10. Lambert SL, Martinez OM, J Immunol 2007 179 8225 8234 18056366
113. Quantitative and qualitative assessment of human immunodeficiency virus type 1 (HIV-1)-specific CD4+ T cell immunity to gag in HIV-1-infected individuals with differential disease progression: reciprocal interferon-gamma and interleukin-10 responses. Ostrowski MA, Gu JX, Kovacs C, Freedman J, Luscher MA, MacDonald KS, J Infect Dis 2001 184 1268 1278 10.1086/324005 11679915 (Pubitemid 33055571)
114. HCV-specific cytokine induction in monocytes of patients with different outcomes of hepatitis C. Woitas RP, Petersen U, Moshage D, Brackmann HH, Matz B, Sauerbruch T, Spengler U, World j gastroenterol WJG 2002 8 562 566 (Pubitemid 34692765)
115. SOCS proteins, cytokine signalling and immune regulation. Yoshimura A, Naka T, Kubo M, Nat Rev Immunol 2007 7 454 465 10.1038/nri2093 17525754 (Pubitemid 46834848)
116. Negative regulation of MyD88-dependent signaling by IL-10 in dendritic cells. Chang J, Kunkel SL, Chang CH, Proc Natl Acad Sci USA 2009 106 18327 18332 10.1073/pnas.0905815106 19815506
117. General nature of the STAT3-activated anti-inflammatory response. El Kasmi KC, Holst J, Coffre M, Mielke L, de Pauw A, Lhocine N, Smith AM, Rutschman R, Kaushal D, Shen Y, et al. J Immunol 2006 177 7880 7888 17114459 (Pubitemid 44846303)
118. Interleukin-10 and the interleukin-10 receptor. Moore KW, de Waal MR, Coffman RL, O'Garra A, Annu Rev Immunol 2001 19 683 765 10.1146/annurev.immunol. 19.1.683 11244051 (Pubitemid 32368050)
119. STAT3-mediated anti-inflammatory signalling. Murray PJ, Biochem Soc Trans 2006 34 1028 1031 17073743 (Pubitemid 46768982)
120. Interleukin-10 inhibits tumor necrosis factor-alpha production in lipopolysaccharide-stimulated RAW 264.7 cells through reduced MyD88 expression. Dagvadorj J, Naiki Y, Tumurkhuu G, Hassan F, Islam S, Koide N, Mori I, Yoshida T, Yokochi T, Innate immunity 2008 14 109 115 10.1177/1753425908089618 18713727
121. Interleukin-10 in viral diseases and cancer: exiting the labyrinth? Vicari AP, Trinchieri G, Immunol Rev 2004 202 223 236 10.1111/j.0105-2896.2004. 00216.x 15546396 (Pubitemid 39576915)
122. Cytokine cascade in dengue hemorrhagic fever: implications for pathogenesis. Chaturvedi UC, Agarwal R, Elbishbishi EA, Mustafa AS, FEMS Immunol Med Microbiol 2000 28 183 188 10.1111/j.1574-695X.2000.tb01474.x 10865168 (Pubitemid 32939398)
123. IL-10, T cell exhaustion and viral persistence. Blackburn SD, Wherry EJ, Trends Microbiol 2007 15 143 146 10.1016/j.tim.2007.02.006 17336072 (Pubitemid 46528253)
124. IL-10 blockade facilitates DNA vaccine-induced T cell responses and enhances clearance of persistent virus infection. Brooks DG, Lee AM, Elsaesser H, McGavern DB, Oldstone MB, J exper med 2008 205 533 541 10.1084/jem.20071948 (Pubitemid 351439301)
125. Relationship of preexisting dengue virus (DV) neutralizing antibody levels to viremia and severity of disease in a prospective cohort study of DV infection in Thailand. Endy TP, Nisalak A, Chunsuttitwat S, Vaughn DW, Green S, Ennis FA, Rothman AL, Libraty DH, J Infect Dis 2004 189 990 1000 10.1086/382280 14999601 (Pubitemid 38373090)
126. A model of DENV-3 infection that recapitulates severe disease and highlights the importance of IFN-gamma in host resistance to infection. Costa VV, Fagundes CT, Valadao DF, Cisalpino D, Dias AC, Silveira KD, Kangussu LM, Avila TV, Bonfim MR, Bonaventura D, et al. PLoS Negl Trop Dis 2012 6 1663 10.1371/journal.pntd.0001663 22666512
127. IL-10 induction by Bordetella parapertussis limits a protective IFN-gamma response. Wolfe DN, Karanikas AT, Hester SE, Kennett MJ, Harvill ET, J Immunol 2010 184 1392 1400 10.4049/jimmunol.0803045 20042578
128. The complex role of interleukin-10 in autoimmunity. Groux H, Cottrez F, J Autoimmun 2003 20 281 285 10.1016/S0896-8411(03)00044-1 12791313 (Pubitemid 36677519)
129. Can interleukin-10 be used as a true immunoregulatory cytokine? Wakkach A, Cottrez F, Groux H, Eur Cytokine Netw 2000 11 153 160 10903794
130. Cytokines: promoters and dampeners of autoimmunity. Hill N, Sarvetnick N, Curr Opin Immunol 2002 14 791 797 10.1016/S0952-7915(02)00403-X 12413531 (Pubitemid 35292428)